Medical Device News Magazine

Maruha Nichiro Announces Strategic Investment and Development Collaboration with Umami Bioworks on the Development of Cultivated Seafood in Japan

The Japanese fishing giant will access Umami Bioworks’ cell cultivation development and manufacturing platform as part of a collaboration to develop and commercialize cultivated seafood production in Japan and beyond

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...
Umami Bioworks (formerly known as Umami Meats), a Singapore-headquartered company developing the development and manufacturing system for producing cultivated seafood, announced their official collaboration with Japan’s largest fishing company, Maruha Nichiro (TYO: 1333). This is the first time a Japanese seafood company has chosen to invest in and collaborate with a foreign cell-cultivated seafood company.
Background:
While the demand for seafood has been growing worldwide, supply shortages are becoming a huge risk due to factors like overfishing and marine pollution. These challenges have led to decreasing wild-catch volumes, as well as health concerns around microplastics and heavy chemicals in seafood. In particular, Japan’s self-sufficiency rate for seafood remains at a low level of 55%, while the domestic wild-catch volumes have decreased approximately 65% over the last 30 years. This poses great risks not only to consumers, but also to the Japanese seafood industry, fishermen, and the overall economy.
Under such circumstances, cultivated products have attracted worldwide attention, with global investment in cultivated products reaching $2.8 billion in 2022. However, many Japanese companies are still lagging behind in participating actively in this industry. Maruha Nichiro has stepped up as a leader to ensure a sustainable supply of seafood worldwide, and to make its first formal investment in cellular agriculture with the aim of laying the foundation for Japan’s cell-cultivated seafood industry.
Umami Bioworks and Maruha Nichiro will be working to build the infrastructure of Japan’s cultivated seafood industry together in this partnership. The strategic investment from Maruha Nichiro will help accelerate Umami’s development progress. The two companies will also carry out a multi-faceted collaboration to accelerate the path to cultivated seafood commercialization, particularly in novel ETP (endangered, threatened and protected) species that have global relevance.
With this investment, Umami Bioworks will be able to expedite their long-term plan of building a research and commercial team in Japan. In turn, Maruha Nichiro will have a third method of sustainable production, other than fishing and aquaculture, for increasingly scarce seafood species.
By establishing a production pipeline of cell-cultivated products for the Japanese market, both companies will develop a foundation for cell-cultivated in Japan and provide the market with a sustainable and stable supply of locally produced seafood.
Mihir Pershad, CEO of Umami Bioworks, “Our seminal partnership with Maruha Nichiro, a global leader in crafting beloved food products, is a pivotal step in achieving our mission of addressing the challenge of feeding a growing global population while minimizing environmental impact. We have the development and production technology, but we require experienced partners with global reach that can help us manufacture and deliver cultivated products to consumers. Through collaborations with industry leaders like Maruha Nichiro, we can leverage our technology expertise to support co-development of delicious, nutritious, and appealing consumer products that secure a healthier and more sustainable food future for the world.”
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”